Translational Research Working Group Developmental Pathway for Biospecimen-Based Assessment Modalities
Authors:
- Ernest T. HawkEHErnest T. Hawk
- for the Translational Research Working GroupFGfor the Translational Research Working Group
Open Access
- 14 September 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (18) , 5672-5677
Abstract
The Translational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of National Cancer Institute's investment in translational research and envision its future. The TRWG conceptualized translational research as a set of six developmental processes or pathways focused on various clinical goals. One of those pathways describes the development of biospecimen-based assays that use biomarkers for the detection, diagnosis, and prognosis of cancer and the assessment of response to cancer treatment. The biospecimen-based assessment modality pathway was conceived not as comprehensive description of the corresponding real-world processes but rather as a tool designed to facilitate movement of a candidate assay through the translational process to the point where it can be handed off for definitive clinical testing. This paper introduces the pathway in the context of prior work and discusses key challenges associated with the biomarker development process in light of the pathway.Keywords
This publication has 10 references indexed in Scilit:
- The Translational Research Working Group Developmental Pathways: Introduction and OverviewClinical Cancer Research, 2008
- Cancer Biomarkers2007
- Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast CancerJournal of Clinical Oncology, 2006
- Bias as a threat to the validity of cancer molecular-marker researchNature Reviews Cancer, 2005
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- Rules of evidence for cancer molecular-marker discovery and validationNature Reviews Cancer, 2004
- Vysis®UroVysion for the detection of urothelial carcinomaExpert Review of Molecular Diagnostics, 2003
- Phases of Biomarker Development for Early Detection of CancerJNCI: Journal of the National Cancer Institute, 2001
- The Development of a Multitarget, Multicolor Fluorescence in Situ Hybridization Assay for the Detection of Urothelial Carcinoma in UrineThe Journal of Molecular Diagnostics, 2000
- Enzymatic production of single-stranded DNA as a target for fluorescence in situ hybridizationChromosoma, 1988